Business Context and Reporting Period
Company: Bionano Genomics, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: March 1, 2022
Reporting Period: Fourth quarter and fiscal year ended December 31, 2021.
This filing serves as a notification that the Company issued a press release on March 1, 2022, detailing its financial results for the specified period. The full text of the press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus prior periods are detailed in the text of this Form 8-K. The document solely references the issuance of the press release containing the comparative financial results.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a standard disclaimer in accordance with General Instruction B.2 of Form 8-K. It states that the information contained in the press release (Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Guidance and Risks: The text of this specific filing does not contain forward-looking guidance, risk factors, or contingencies. These items would be located in the attached press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2021 revenue and net loss figures.
- Verify cash position and burn rate details in the attached press release.
- Check for any updated full-year 2022 guidance provided in the press release.
- Confirm the status of the Company's warrants (BNGOW) and common stock (BNGO) trading on The Nasdaq Stock Market.